The Thoracic Oncology Research Initiative (TORI), led by Dr. Sharon Pine, brings together investigators from multiple departments and centers across the CU Anschutz Medical Campus to advance lung cancer research.
Dr. Lieu discusses what a stage 4 colon cancer diagnosis means for patients and treatment methods.
Clinical trials over the years have resulted in new drugs that prolong life and prevent cancer from spreading and Dr. Diamond discusses their importance and impact in breast cancer research.
Ross Camidge, MD, PhD, received the Daniel C. Ihde Lectureship Award for Medical Oncology from the International Association for the Study of Lung Cancer. The award is named for the influential lung cancer researcher and former longtime deputy director of the National Cancer Institute.
Robert Lentz, MD, received funding to test the combination of two drugs in colorectal and pancreas ductal adenocarcinoma. “Metastatic colorectal and pancreas ductal adenocarcinoma are common and deadly and frequently harbor KRAS mutations, novel treatments are desperately needed.”
Thanks to a grant from the Gilead Sciences Research Scholars Program, University of Colorado Cancer Center member Tejas Patil, MD, is launching a study to better understand how persister cells survive in the presence of targeted therapy and what methods might be used to target them to improve patient survival.
In the earliest days of specialized cancer care, either individual oncologists were burdened with the expectation to know everything, or patients were sent on treatment journeys that could involve multiple visits with multiple clinicians in multiple locations. Drs. Lieu and Kim discuss the benefits of multidisciplinary care.
Dr. Davila received R01 grant funding from the NCI to better understand why some melanoma patients don’t respond to immunotherapy, and to determine how to increase responsiveness in patients, eventually resulting in a Phase I clinical trial in patients with rare melanoma.
Jamie Studts, PhD, has co-created a project designed to boost lung cancer screening rates in Kentucky earning a grant from the Bristol Myers Squibb Foundation.
Dr. Laura Graham, is currently leading a phase 2 trial studying whether high doses of testosterone are a feasible treatment against castration-resistant prostate cancer (CRPC) leading to a reduction in prostate cancer growth as well as improved quality of life.
PIKE-PREP offers students from URM communities multi-dimensional mentorship and research training designed to prepare them for enrollment and success in a top-tier PhD or MD/PhD program.